Login / Signup

The dilemma of whether to continue TNFα blocker therapy in an ulcerative colitis patient newly diagnosed with a malignant melanoma and melanoma in situ.

Louise ZuzarteSara MirhadiRichard A CarrSimon Tso
Published in: BMJ case reports (2019)
Keyphrases
  • newly diagnosed
  • ulcerative colitis
  • rheumatoid arthritis
  • case report
  • angiotensin converting enzyme
  • stem cells
  • mesenchymal stem cells
  • cell therapy
  • angiotensin ii
  • basal cell carcinoma